Orane Benoît
Last year student at the National graduate school of chemistry of Montpellier in combination with a Master's degree at the Faculty of Pharmacy. Currently in internship at Myelo Therapeutics.
Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs. Its lead compound, myelo001, is a small molecule that is effective on the hematogenesis. Its oral application is being investigated as a treatment for - chemotherapy-induced myelosuppression (CIM), including chemotherapy-induced neutropenia (CIN), chemotherapy-induced thrombocytopenia, and chemotherapy-induced lymphocytopenia - radiation-induced myelosuppression (RIM) - acute radiation syndrome (ARS).
